Found: 9
Select item for more details and to access through your institution.
Copper Catalysis in Living Systems and In Situ Drug Synthesis.
- Published in:
- Angewandte Chemie, 2016, v. 128, n. 50, p. 15891, doi. 10.1002/ange.201609837
- By:
- Publication type:
- Article
EXAMINING THE PAST, PRESENT, AND FUTURE OF AN ICONIC MOJAVE DESERT SPECIES, THE JOSHUA TREE (YUCCA BREVIFOLIA, YUCCA JAEGERIANA).
- Published in:
- Southwestern Naturalist, 2020, v. 65, n. 3/4, p. 216, doi. 10.1894/0038-4909-65.3-4.216
- By:
- Publication type:
- Article
Copper Catalysis in Living Systems and In Situ Drug Synthesis.
- Published in:
- Angewandte Chemie International Edition, 2016, v. 55, n. 50, p. 15662, doi. 10.1002/anie.201609837
- By:
- Publication type:
- Article
scRNA Transcription Profile of Adult Zebrafish Podocytes Using a Novel Reporter Strain.
- Published in:
- Cellular Physiology & Biochemistry (Cell Physiol Biochem Press GmbH & Co. KG), 2021, p. 35, doi. 10.33594/000000366
- By:
- Publication type:
- Article
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.
- Published in:
- Nature Medicine, 2003, v. 9, n. 9, p. 1209, doi. 10.1038/nm918
- By:
- Publication type:
- Article
Investigating the RAS can be a fishy business: interdisciplinary opportunities using Zebrafish.
- Published in:
- Clinical Science, 2018, v. 132, n. 23, p. 2469, doi. 10.1042/CS20180721
- By:
- Publication type:
- Article
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00571-w
- By:
- Publication type:
- Article
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice